Celltrion UK has officially opened its new UK headquarters at the Charter Building in Uxbridge, UK, reinforcing the company's dedication to long-term growth and partnership in the UK market. The opening ceremony was attended by H young-Ki Kim, CEO and Vice Chairman at Celltrion, Rosalind Campion, Director of the Office for Life Sciences and Mark Samuels, Chief Executive of Medicines UK, and the British Biosimilars Association. The event was marked with a ribbon cutting ceremony.
Strategically located in the heart of Uxbridge, the new office will serve as Celltrion UK's central hub for UK operations. This move places Celltrion among a growing list of life sciences companies including Regeneron, Amgen, Gilead Sciences, Daiichi Sankyo, that have established presence in Uxbridge - emerging as a leading hub for biotechnology and pharmaceutical innovation. The new headquarters also reflects continued growth for Celltrion UK, which has expanded its headcount by 20% over the past year.
With an exciting pipeline of new products spanning across multiple therapeutic areas including allergy, endocrinology, ophthalmology and immunology anticipated over the coming years, the company expects further recruitment and investment in the coming years. This move is the latest chapter in Celltrion's long-term vision for the UK, demonstrating its dedication to being a trusted healthcare partner, a contributor to the UK economy, and a key player in the global biosimilars market.
